Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR103 in Relapsed Advanced Malignancies (BHARAT-1)
NCT05607199Phase 1Terminated
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AUR103 in solid tumor, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoint: Optimal Biological Dose at 16 weeks. Started Sep 2022; status: terminated.
02
Drugs
AUR103
03
Conditions
solid tumoracute myeloid leukemia (AML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05607199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607199.